Company Overview of Targazyme, Inc.
Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...
3200 County Road 104
Floresville, TX 78114
Founded in 2005
Key Executives for Targazyme, Inc.
Co-Founder, Chairman and Chief Executive Officer
Head of Operations and Vice President of CMC
Senior Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2016.
Targazyme, Inc. Key Developments
Targazyme Enrolls First Patient in Phase 1/2 Study of TZ101 Fucosylated Regulatory T Cells
Jul 20 16
Targazyme, Inc. announced that it has enrolled the first patient in a Phase 1/2 TZ 101-treated regulatory T cell clinical study. This Phase 1/2 clinical study will evaluate the efficacy and safety of TZ101-treated regulatory T cells in the prevention and treatment of acute and chronic Graft-Versus-Host-Disease ("GVHD") in stem cell transplants. This clinical milestone will hopefully translate into the clinic the recent preclinical findings published in the journal Blood demonstrating the effectiveness of ex vivo treatment of regulatory T-cells with TZ101 in the prevention of GVHD.
Targazyme, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:45 AM
Dec 14 15
Targazyme, Inc. Presents at 18th Annual BIO CEO & Investor Conference 2016, Feb-08-2016 11:45 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, New York, United States.
Targazyme Collaborates with the University of Minnesota Medical Center
Nov 16 15
Targazyme has collaborated with the University of Minnesota Medical Center. It was reported that the collaboration is aimed at advancing the development of the company's clinical product candidate, TZ101 for use with regulatory T cells. It is based on positive proof of concept data published in the journal 'Blood' demonstrating that ex vivo treatment of Tregs with TZ101 prior to administration is an effective strategy for the prevention of Graft-Versus-Host-Disease. The new partnership will concentrate on improving understanding of the mechanisms involved with TZ101-treated Treg immunotherapy in the transplant and autoimmune disease settings.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries